www.fdanews.com/articles/87631-k-v-pharmaceutical-hold-target-price-reduced
K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED
June 16, 2006
Analysts at Deutsche Bank Securities maintain their "hold" rating on K-V Pharmaceutical. The target price has been reduced from $26 to $20.
Newratings